GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adicet Bio Inc (STU:1IJA) » Definitions » Notes Receivable

Adicet Bio (STU:1IJA) Notes Receivable : €0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Adicet Bio Notes Receivable?

Adicet Bio's Notes Receivable for the quarter that ended in Dec. 2024 was €0.00 Mil.


Adicet Bio Notes Receivable Historical Data

The historical data trend for Adicet Bio's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adicet Bio Notes Receivable Chart

Adicet Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Notes Receivable
Get a 7-Day Free Trial - - - - -

Adicet Bio Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Adicet Bio Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Adicet Bio Notes Receivable Related Terms

Thank you for viewing the detailed overview of Adicet Bio's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Adicet Bio Business Description

Traded in Other Exchanges
Address
131 Dartmouth Street, 3rd Floor, Boston, MA, USA, 02116
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Adicet Bio Headlines

No Headlines